The annual Vanderbilt-Ingram Cancer Center Scientific Retreat will be held Thursday, May 3, 8 a.m. to 3 p.m. at the Vanderbilt Student Life Center. The potential link between the body’s microbiome and cancer is the topic of this year’s event.
Sirtex Medical Ltd. has renewed a grant award to Dan Brown, MD, professor of Radiology and Radiological Sciences and chief of Interventional Oncology, and his Vanderbilt Health colleagues, for a research program designed to treat patients with liver tumors that cannot be addressed with surgery.
Vito Quaranta, MD, and colleagues have found that treated melanoma cells enter a previously unrecognized “idling” state. These idling cells may be primed to acquire resistance mutations and may constitute the bulk of residual disease.
Human tumors appear to have a broken circadian clock, researchers at Vanderbilt University Medical Center report in the journal PeerJ.
Many types of cancer cells escape the body’s effort to kill them by overexpressing MCL-1, a protein important for blocking apoptosis, or programmed cell death. A recent study by Vivian Gama, PhD and colleagues indicates that MCL-1 also helps maintain the identity and ability of stem cells to differentiate, or give rise to other kinds of cells.
Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancerThursday, March 22nd, 2018
Boehringer Ingelheim and Vanderbilt University recently announced the expansion of their successful existing collaboration to develop novel anti-cancer compounds.
Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.
A new study by W. Kimryn Rathmell, MD, PhD, and colleagues, reveals a gene mutation’s role in Von Hippel-Lindau syndrome, a genetically inherited disease which causes tumor growth in several organs.
Christine Lovly, MD, PhD, assistant professor of Medicine, has received a $200,000 grant to support promising new research on lung cancer.
A new study by Dai Chung, MD, and colleagues reports that a protein, called SIRT6, plays an important role in the growth of neuroblastoma and suggests that SIRT6 may be a target for new therapeutics for the disease.